Ligand Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Ligand Reports Second Quarter 2016 Financial Results
August 5, 2016 6:45 AM EDT
Deutsche Bank downgraded Ligand Pharma (NASDAQ: LGND) from Hold to Sell with a price target of $110.00 (from $104.00). The downgrade was tied to valuation.
Analyst Gregg Gilbert said, "Our model and $110 target factor in continued growth for key royalty drivers (particularly AMGNs Kyprolis and Novartis Promacta), growth in technology deals (tied to Captisol and other platforms), and launches of new... More
August 4, 2016 8:56 AM EDT
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $0.50, $0.10 better than the analyst estimate of $0.40. Revenue for the quarter came in at $19.5 million versus the consensus estimate of $18.12 million.
The Company affirms expectations for full-year 2016 total revenues to be between $115 million and $119... More
